-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 12, Amgen announced that it has reached an agreement with Horizon Therapeutics to acquire the latter
for about $28 billion.
Founded in 2008 and headquartered in Dublin, Ireland, Horizon is a biopharmaceutical company
focused on rare diseases and rheumatology.
Horizon's innovative ophthalmic rare disease therapy Tepezza, a monoclonal antibody targeting IGF-1R, was first approved by the FDA in January 2020 for the treatment of thyroid eye disease
.
Horizon's products are also marketed as Krystexxa, which treats chronic gout, Uplizna, which treats inflammation of the optic nerve and spinal cord, and Ravicti
, which treats urea cycle disorders for a rare genetic disease.
.
Amgen's Chairman and Chief Executive Officer Robert A.
Mr.
Bradway said, "The acquisition of Horizon is an irresistible opportunity for Amgen and is in line with our strategy to achieve long-term growth
by providing innovative medicines to meet the needs of patients with serious diseases.
Amgen's decades of leadership in inflammation and kidney disease, combined with our global reach and world-class biologics capabilities, will enable us to help more patients
with 'first-in-class' drugs such as Tepezza, Krystexxa and Uplizina.
" In addition, potential new drugs in the Horizon pipeline complement our own R&D portfolio
.
”
Tim, Chairman, President and Chief Executive Officer of Horizon
Commenting on today's announcement, Mr.
Walbert said, "For almost 15 years, we have built one of
the fastest growing and most respected companies in the biotechnology industry from the start.
We have achieved great things
for our patients, their families, and our clients.
These achievements stem from the deep commitment, dedication and passion
of our staff to patients affected by rare autoimmune and severe inflammatory diseases.
Amgen shares this commitment and enthusiasm to continue to maximize the value of its current portfolio and pipeline and accelerate its ability to
reach more patients globally.
”
Original: _mstmutation="1" _msthash="220728" _msttexthash="10020946">
